Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 25Ovarian Neoplasms 19Neoplasms 12Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 11Endometrial Neoplasms 7Neoplasm Metastasis 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Digestive System Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mouth Neoplasms 2Lymphoid Interstitial Pneumonia 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Breast Neoplasms 2Biliary Tract Neoplasms 2Astrocytoma 2

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemorrhage × Bevacizumab × 30 days × Clear all
NCT07527832 2026-06-03

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Pfizer

Completed
1,000 enrolled
Gastrointestinal

Hemorrhage, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡